Latest in mRCC from ESMO 2022

Bookmark and Share
Published: 12 Sep 2022
Views: 1224
Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard

Dr Javier Puente (Hospital Clinico San Carlos, Madrid, Spain), Dr Bernard Escudier (Institut Gustave Roussy, Villejuif, France), Prof Viktor Grünwald (University Hospital Essen, Essen, Germany) and Prof Stéphane Oudard (Georges Pompidou Hospital, Paris, France) discuss the latest in metastatic renal cell carcinoma.

They initially talk about the results from the COSMIC-313 study.

The study finds that cabozantinib in combination with nivolumab and ipilimumab significantly improves progression-free survival for previously untreated advanced renal cell carcinoma patients.

The panel then discusses the CLEAR study and what it means for aRCC patients. They then mention the phase II LITESPARK-003 study exploring belzutifan plus cabozantinib as the first-line treatment of advanced renal cell carcinoma (RCC).

They conclude by discussing the results from the phase III randomised PIVOT-09 study.

This programme is supported by an unrestricted educational grant from Eisai.